Search

Your search keyword '"Scialabba, Francesco"' showing total 10 results
Start Over Author "Scialabba, Francesco"
10 results on '"Scialabba, Francesco"'

1. A comparative study using insulin pump therapy and continuous glucose monitoring in newly diagnosed very young children with type 1 diabetes: it is possible to bend the curve of HbA1c

Author

Castorani, Valeria, Favalli, Valeria, Rigamonti, Andrea, Frontino, Giulio, Di Tonno, Raffaella, Morotti, Elisa, Sandullo, Federica, Scialabba, Francesco, Arrigoni, Francesca, Dionisi, Benedetta, Foglino, Riccardo, Morosini, Camilla, Olivieri, Gabriele, Barera, Graziano, Meschi, Franco, and Bonfanti, Riccardo

Published
2023
Full Text
View/download PDF

2. Pump Therapy and Use of Technologies

Author

Di Tonno, Raffaella, Castorani, Valeria, Raouf, Tara, Rigamonti, Andrea, Frontino, Giulio, Favalli, Valeria, Morotti, Elisa, Sandullo, Federica, Aracu, Claudia, Scialabba, Francesco, Bonfanti, Riccardo, Rabbone, Ivana, editor, and Iafusco, Dario, editor

Published
2023
Full Text
View/download PDF

3. Sustained effectiveness of an advanced hybrid closed loop system in a cohort of children and adolescents with type 1 diabetes: a one-year real-world study

Author

Passanisi, Stefano, primary, Salzano, Giuseppina, primary, Bombaci, Bruno, primary, Minuto, Nicola, primary, Bassi, Marta, primary, Bonfanti, Riccardo, primary, Scialabba, Francesco, primary, Mozzillo, Enza, primary, Di Candia, Francesca, primary, Monti, Sara, primary, Graziani, Vanna, primary, Maffeis, Claudio, primary, Anita Piona, Claudia, primary, Arnaldi, Claudia, primary, Tosini, Davide, primary, Felappi, Barbara, primary, Roppolo, Rosalia, primary, Zanfardino, Angela, primary, Delvecchio, Maurizio, primary, Lo Presti, Donatella, primary, Calzi, Elena, primary, Ripoli, Carlo, primary, Franceschi, Roberto, primary, Reinstadler, Petra, primary, Rabbone, Ivana, primary, Maltoni, Giulio, primary, Alibrandi, Angela, primary, Zucchini, Stefano, primary, Marigliano, Marco, primary, and Lombardo, Fortunato, primary

Published
2024
Full Text
View/download PDF

4. Turning the tides: achieving rapid and safe glucose control in adolescents with suboptimally controlled type 1 diabetes using advanced hybrid closed loop systems

Author

Castorani, Valeria, primary, Rigamonti, Andrea, additional, Frontino, Giulio, additional, Morotti, Elisa, additional, Sandullo, Federica, additional, Scialabba, Francesco, additional, Arrigoni, Francesca, additional, Dionisi, Benedetta, additional, Foglino, Riccardo, additional, Morosini, Camilla, additional, Olivieri, Gabriele, additional, and Bonfanti, Riccardo, additional

Published
2024
Full Text
View/download PDF

5. Sustained Effectiveness of an Advanced Hybrid Closed-Loop System in a Cohort of Children and Adolescents With Type 1 Diabetes: A 1-Year Real-World Study.

Author

Passanisi, Stefano, Salzano, Giuseppina, Bombaci, Bruno, Minuto, Nicola, Bassi, Marta, Bonfanti, Riccardo, Scialabba, Francesco, Mozzillo, Enza, Di Candia, Francesca, Monti, Sara, Graziani, Vanna, Maffeis, Claudio, Piona, Claudia Anita, Arnaldi, Claudia, Tosini, Davide, Felappi, Barbara, Roppolo, Rosalia, Zanfardino, Angela, Delvecchio, Maurizio, and Lo Presti, Donatella

Subjects
TYPE 1 diabetes, CLOSED loop systems, GLYCOSYLATED hemoglobin, TEENAGERS
Abstract

OBJECTIVE: To investigate glucose metrics and identify potential predictors of the achievement of glycemic outcomes in children and adolescents during their first 12 months of MiniMed 780G use. RESEARCH DESIGN AND METHODS: This multicenter, longitudinal, real-world study recruited 368 children and adolescents with type 1 diabetes (T1D) starting SmartGuard technology between June 2020 and June 2022. Ambulatory glucose profile data were collected during a 15-day run-in period (baseline), 2 weeks after automatic mode activation, and every 3 months. The influence of covariates on glycemic outcomes after 1 year of MiniMed 780G use was assessed. RESULTS: After 15 days of automatic mode use, all glucose metrics improved compared with baseline (P < 0.001), except for time below range (P = 0.113) and coefficient of variation (P = 0.330). After 1 year, time in range (TIR) remained significantly higher than at baseline (75.3% vs. 62.8%, P < 0.001). The mean glycated hemoglobin (HbA1c) over the study duration was lower than the previous year (6.9 ± 0.6% vs. 7.4 ± 0.9%, P < 0.001). Time spent in tight range (70–140 mg/dL) was 51.1%, and the glycemia risk index was 27.6. Higher TIR levels were associated with a reduced number of automatic correction boluses (P < 0.001), fewer SmartGuard exits (P = 0.021), and longer time in automatic mode (P = 0.030). Individuals with baseline HbA1c >8% showed more relevant improvement in TIR levels (from 54.3% to 72.3%). CONCLUSIONS: Our study highlights the sustained effectiveness of MiniMed 780G among youth with T1D. Findings suggest that even children and adolescents with low therapeutic engagement may benefit from SmartGuard technology. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. MiniMed 780G Six-Month Use in Children and Adolescents with Type 1 Diabetes: Clinical Targets and Predictors of Optimal Glucose Control

Author

Lombardo, Fortunato, primary, Passanisi, Stefano, additional, Alibrandi, Angela, additional, Bombaci, Bruno, additional, Bonfanti, Riccardo, additional, Delvecchio, Maurizio, additional, Di Candia, Francesca, additional, Mozzillo, Enza, additional, Piccinno, Elvira, additional, Piona, Claudia Anita, additional, Rigamonti, Andrea, additional, Scialabba, Francesco, additional, Maffeis, Claudio, additional, and Salzano, Giuseppina, additional

Published
2023
Full Text
View/download PDF

8. Non-Occlusive Mesenteric Ischemia in Children With Diabetic Ketoacidosis: Case Report and Review of Literature

Author

Frontino, Giulio, Di Tonno, Raffaella, Castorani, Valeria, Rigamonti, Andrea, Morotti, Elisa, Sandullo, Federica, Scialabba, Francesco, Arrigoni, Francesca, Foglino, Riccardo, Dionisi, Benedetta, Ferri, Chiara Irene Carla, Zirpoli, Salvatore, Barera, Graziano, Meschi, Franco, Bonfanti, Riccardo, Frontino, Giulio, Di Tonno, Raffaella, Castorani, Valeria, Rigamonti, Andrea, Morotti, Elisa, Sandullo, Federica, Scialabba, Francesco, Arrigoni, Francesca, Foglino, Riccardo, Dionisi, Benedetta, Ferri, Chiara Irene Carla, Zirpoli, Salvatore, Barera, Graziano, Meschi, Franco, and Bonfanti, Riccardo

Subjects
non-occlusive mesenteric ischemia (NOMI), continuous subcutaneous insulin infusion) [insulin pump (CSII], Adolescent, Endocrinology, Diabetes and Metabolism, DKA (diabetic ketoacidosis), Abdominal Pain, Diabetic Ketoacidosis, T1DM (type 1 diabetes mellitus), Diabetes Mellitus, Type 1, acute kidney injury, hyperosmolar (hyperglycemic) coma, Mesenteric Ischemia, Humans, Female, Child
Abstract

IntroductionDespite the use of technology, recurrent diabetic ketoacidosis (DKA) prevention remains an unmet need in children and adolescents with T1D and may be accompanied by life-threatening acute complications. We present a rare case of non-occlusive mesenteric ischemia (NOMI) with overt manifestation after DKA resolution and a discussion of recent literature addressing DKA-associated NOMI epidemiology and pathogenesis in children and adolescents.Case PresentationA 13-year-old female with previously diagnosed T1D, was admitted at our emergency department with hypovolemic shock, DKA, hyperosmolar state and acute kidney injury (AKI). Mildly progressive abdominal pain persisted after DKA correction and after repeated ultrasound evaluations ultimately suspect for intestinal perforation, an intraoperative diagnosis of NOMI was made.ConclusionThe diagnosis of DKA-associated NOMI must be suspected in pediatric patients with DKA, persistent abdominal pain, and severe dehydration even after DKA resolution.

Published
2022
Full Text
View/download PDF

9. MiniMed™ 780G six-month use on children and adolescents with type 1 diabetes: clinical targets and predictors of optimal glucose control

Author

Fortunato Lombardo, Stefano Passanisi, Angela Alibrandi, Bruno Bombaci, Riccardo Bonfanti, Maurizio Delvecchio, Francesca Di Candia, Enza Mozzillo, Elvira Piccinno, Claudia Anita Piona, Andrea Rigamonti, Francesco Scialabba, Claudio Maffeis, Giuseppina Salzano, Lombardo, Fortunato, Passanisi, Stefano, Alibrandi, Angela, Bombaci, Bruno, Bonfanti, Riccardo, Delvecchio, Maurizio, Di Candia, Francesca, Mozzillo, Enza, Piccinno, Elvira, Piona, Claudia Anita, Rigamonti, Andrea, Scialabba, Francesco, Maffeis, Claudio, and Salzano, Giuseppina

Subjects
Pediatric, Medical Laboratory Technology, Technology, Endocrinology, Coefficient of variation, Glycated hemoglobin, children, Advanced hybrid closed loop, type 1 diabetes, Endocrinology, Diabetes and Metabolism, Time in range, insulin pump, Education
Abstract

Background: The aim of this multicenter observational real-world study was to investigate glycemic outcomes in children and adolescents with type 1 diabetes over the first 6-month use of MiniMed™ 780G. The secondary objective was to evaluate demographic and clinical factors that may be significantly associated with the achievement of therapeutic goals. Methods: Demographic, anamnestic, and clinical data of study participants were collected at the time of enrollment. Data on ambulatory glucose profile were acquired at 3 and 6 months after activating automatic mode. Aggregated glucose metrics and device settings of the entire study period were analyzed to identify predictors of optimal glycemic control, assessed by the concomitant achievement of time in range (TIR) >70%, coefficient of variation (CV)

Published
2023

10. A retrospective analysis of 24-month real-world glucose control for children and adolescents with type 1 diabetes using the MiniMed™ 670G insulin pump

Author

Maurizio Delvecchio, Alessio Galati, Claudio Maffeis, Stefano Passanisi, Riccardo Bonfanti, Roberto Franceschi, Gianluca Tornese, Elena Calzi, Angela Zanfardino, Giulia Patrizia Bracciolini, Elvira Piccinno, Alberto Sabbion, Fortunato Lombardo, Elena Fornari, Giuseppina Salzano, Andrea Rigamonti, Francesco Scialabba, Vittoria Cauvin, Elena Faleschini, Dario Iafusco, Caterina Grosso, Cinzia Ciullo, Graziella Fichera, Irene Rutigliano, Delvecchio, Maurizio, Galati, Alessio, Maffeis, Claudio, Passanisi, Stefano, Bonfanti, Riccardo, Franceschi, Roberto, Tornese, Gianluca, Calzi, Elena, Zanfardino, Angela, Patrizia Bracciolini, Giulia, Piccinno, Elvira, Sabbion, Alberto, Lombardo, Fortunato, Fornari, Elena, Salzano, Giuseppina, Rigamonti, Andrea, Scialabba, Francesco, Cauvin, Vittoria, Faleschini, Elena, Iafusco, Dario, Grosso, Caterina, Ciullo, Cinzia, Fichera, Graziella, and Rutigliano, Irene

Subjects
continuous glucose monitoring (CGM), CSII, insulin pump therapy, realworld evidence, type 1 diabetes
Abstract

The MiniMed™ 670G insulin pump was the first hybrid closed-loop (HCL) system available for clinical use. Data on metabolic outcomes in children, adolescents and young adults over the first 12 months with auto-mode use of this device are available, but no data with longer follow-up have been published. We aimed to assess the metabolic outcomes in children and adolescents using the MiniMed™ 670G for 24 months.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results